UNSPSC 51161543: Oxarbazole

This classification denotes an anti-asthmatic agent with the molecular formula C21H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A34YCH7N8A, chemically known as 9-benzoyl-1,2,3,4-tetrahydro-6-methoxycarbazole-3-carboxylic acid but generally known as oxarbazole, which bears US NIH Compound Identifier 37184. European Medicines Agency schedules Oxarbazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09503MIG.

UNSPSC 51161543 Oxarbazole is a Commodity code for a specific pharmaceutical active ingredient, but state and local procurement activity under this code shows no direct opportunities for oxarbazole itself. The single recent posting—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—uses a higher-level taxonomy classification that spans pharmaceutical manufacturing and wholesale supply across many drug substances and formulations, not oxarbazole in isolation. State and local health systems, correctional facilities, and other government entities procure pharmaceuticals through cooperative purchasing frameworks that aggregate demand across multiple jurisdictions to negotiate volume pricing and ensure supply-chain compliance with cGMP and DSCSA requirements. Issuing bodies under this broader pharmaceutical-purchasing activity include state health departments and multistate cooperatives that serve state agencies, counties, cities, and special-purpose districts; MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, is a principal cooperative vehicle that coordinates purchasing for participating states including Oregon.

The MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, requests manufacturers to supply identified pharmaceutical products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with comprehensive pricing in multiple formats (flat price, net price, WAC-minus). Vendors must certify cGMP compliance, maintain relationships with at least two wholesalers with active chargeback systems, and carry insurance including $5 million commercial general liability and $2 million network security and privacy liability. Products must be marketplace-available by May 15, 2026, with contracts effective July 1, 2026 for a two-year term. Evaluation weights pricing competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent each on administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. Geographic concentration is visible in the Midwest and Pacific Northwest—Minnesota as the administering state and Oregon as a participating member—though the MMCAP cooperative structure suggests broader multistate participation not named in the solicitation summary. No specific oxarbazole demand or award value is disclosed; buyers evaluating this Commodity code should treat it as part of the broader generic-pharmaceutical procurement landscape under higher-level family and class codes.